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Abstract
Cardiac glycosides are promising anticancer drugs. We have recently shown that the cardiac glycosides digitoxin, digoxin and ouabain induce selective 
killing of lung cancer cells, and that the cytotoxicity of digitoxin against these cells occurs at concentrations below those observed in the plasma of 
cardiac patients treated with this drug (Oncogene, 2013. doi: 10.1038/onc.2013.229). Here we report that digitoxin, digoxin and ouabain induce a 
potent inhibition of glycolysis (glucose consumption and lactate production) in A549 cells at nanomolar concentrations. This inhibition was comparable 
to that observed with millimolar concentrations of the glycolysis inhibitor dichloroacetate, which is currently undergoing clinical trials for the treatment 
of cancer. Because platinum compounds are commonly used in the treatment of lung cancer, we tested the cytotoxicity of several combinations of 
cisplatin with each cardiac glycoside; these combinations induced synergistic, antagonistic or additive effects mainly depending on the order at which 
the drugs were added to the cells.
Introduction
Cardiac glycosides, also known as cardiotonic steroids, are a group of natural steroidal compounds that contain an unsaturated lactone ring in their 
structure and have the ability to inhibit the Na+/K+-ATPase pump. This lactone moiety defines the two classes of cardiac glycoside: cardenolides (with 
the lactone 2-furanone) and bufadienolides (with the lactone 2-pyrone). Numerous cardiac glycosides have been isolated from plants (e.g. digitoxin, 
digoxin and ouabain) and several have also been found in amphibians and mammals (e.g. digoxin, ouabain and bufalin). Some cardiac glycosides are 
used in cardiology for the treatment of cardiac congestion and some types of cardiac arrhythmias. The mechanism by which these drugs affect cardiac 
contractility is known to be mediated by a highly specific inhibition of Na+/K+-ATPase [1-3]. 
Several reports published over the last several decades suggest that cardiac glycosides have anticancer potential  [4-10]. Evidence suggests that some 
cardiac glycosides induce selective anticancer effects [4, 11-13], which may occur at concentrations commonly found in the plasma of patients treated 
with these drugs [13, 14]. Other reports suggest, however, that cardiac glycosides-induced cytotoxicity is not selective for cancer cells [15]. Some 
cardiac glycosides have shown potent and selective anticancer effects in mice xenografted with human malignant cells [16-19]; however, these results 
may be an experimental artifact caused by the ability of cardiac glycosides to kill human cells versus rodent cells rather than by their ability to kill 
cancer cells versus normal cells [13, 20]. The cardiac drugs digitoxin and digoxin, the semi-synthetic cardiac glycoside UNBS1450, and two extracts from 
Nerium oleander have entered clinical trials for the treatment of cancer (see http://clinicaltrials.gov/ and references [6, 7, 9, 21]).
Recently, we observed that the cardiac glycosides digitoxin, digoxin and ouabain induced selective killing of lung cancer cells, and that the cytotoxicity 
of digitoxin against these cells occurred at concentrations below those commonly observed in the plasma of cardiac patients treated with this drug [13]. 
We have also recently observed that an extract from the cardenolide-containing plant Nerium oleander induced a marked inhibition of glycolysis in lung 
cancer cells [22]. In this article, we report that the cardiac glycosides digitoxin, digoxin and ouabain induce a potent inhibition of glycolysis in lung 
cancer cells at nanomolar concentrations. We also report that specific combinations of these cardiac glycosides with cisplatin may increase the 
cytotoxicity of this commonly used anticancer drug in lung cancer cells.
Material and Methods
Chemicals and cell lines
Digitoxin (97%), digoxin (98.6%), ouabain (95%), cisplatin (99.9%), and dichloroacetate (98%), were purchased from Sigma. The human A549 lung cancer 
cell line and the human embryo lung fibroblastic MRC-5 cell line were purchased from the European Collection of Cell Cultures. The cell lines were 
maintained in DMEM supplemented with 2 mM glutamine, 50 µg/mL penicillin, 50 µg/mL streptomycin and 10% fetal bovine serum, and were cultured at 
37°C in a humidified atmosphere containing 5% CO2. Cell culture reagents were obtained from Life Technologies.
Assay for cytotoxic activity
The MTT assay is a colorimetric technique that allows the quantitative determination of cell viability. It is based on the capability of viable cells to 
transform the MTT salt (3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) into a formazan dye. Exponentially growing cells were seeded 
into 96-well plates and drugs were added 24 h later. Following the incubation period specified in figure and table legends, medium was removed and 
125 µL MTT (1 mg/mL in medium) was added to each well for 4 hours. Then, 80 µL 20% SDS in 0.02 M HCl were added, plates were incubated for 10 
hours at 37 ºC, and optical densities were measured at 540 nm on a multiwell plate spectrophotometer reader. Cell viability was expressed as 
percentage in relation to controls. All data were averaged from at least three independent experiments and were expressed as means ± standard error 
of the means (SEM).
Inhibition of glycolysis
Glycolysis inhibition was assessed by measuring concentrations of glucose (initial product of glycolysis) and lactate (final product of glycolysis) in control 
and treated cells. Briefly, 106 cells were exposed in 6-well plates to the tested compounds for 8 h, and glucose and lactate concentrations were 
determined in cell supernatants by using the Accutrend® Plus analyzer together with Accutrend glucose strips and BM-Lactate Strips (Roche 
Diagnostics). After calibrating the instrument with glucose and lactate calibration strips, test strips were used to determine glucose and lactate levels 
via colorimetric-oxidase mediator reactions according to the manufacturer's instructions [23]. Results are expressed as percentage of lactate production 
and percentage of glucose consumption in relation to untreated cells, and are shown as means ± standard error of the means (SEM) of three 
independent experiments.
Combination Index
A549 cancer cells were exposed for 44-48 h to several concentrations of each cardiac glycoside, cisplatin and each cardiac glycoside in combination with 
cisplatin (the cardiac glycosides were added 4 h before cisplatin or vice versa). Cell viability was assessed by the MTT assay. The parameter 
Combination Index (CI) was calculated with the computer software Compusyn. A CI value <0.90 is considered to be synergism and is represented by 
“+++++” for very strong synergism (CI<0.10), “++++” for strong synergism (CI=0.10-0.30), “+++” for synergism (CI=0.30-0.70), “++” for moderate 
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synergism (CI=0.70-0.85) and “+” for slight synergism (CI=0.85-0.90). A CI value between 0.90 and 1.10 corresponds with additive effect and is indicated 
with “±”. A CI value >1.10 is considered to be antagonism and is represented by “-” for slight antagonism (CI=1.10-1.20), “--” for moderated antagonism 
(CI=1.20-1.45), “---” for antagonism (CI=1.45-3.30), “----” for strong antagonism (CI=3.30-10.00) and “-----” for very strong antagonism (CI>10.00) [24].
Statistical analysis
All data were averaged from at least three independent experiments and were expressed as means ± standard error of the means (SEM). For statistical 
analysis we used the t-test (paired, two-tailed). A P-value >0.05 is not considered statistically significant and is not represented by any symbol. A 
P-value <0.05 is considered to correspond with statistical significance and is indicated with an asterisk (*), a P-value <0.01 is indicated with a double 
asterisk (**), and a P-value <0.001 is indicated with a triple asterisk (***).
Results and Discussion
In a recent work we reported that the cardiac glycosides digitoxin, digoxin and ouabain were more cytotoxic on A549 lung cancer cells than on MRC5 
non-malignant lung fibroblasts [13]. We showed that the IC50 values (means ± SEM, nM) for the cancer cell line and the normal cell line were, 
respectively, 7.39 ± 0.6 and 77.5 ± 12.4 for digitoxin, 8.0 ± 1.3 and 65.1 ± 13.2 for digoxin, and 5.3 ± 0.4 and 29.4 ± 4.5 for ouabain. These data are 
particularly relevant for digitoxin, as this drug was cytotoxic on the cancer cell line at concentrations below those commonly observed in the plasma of 
cardiac patients treated with this drug (20-33 nM). Here we provide graphs showing how the viability of both cell lines was affected by several 
concentrations of each cardiac glycoside and of the anticancer drug cisplatin (Illustration 1).
Cardiac glycosides are known inhibitors of the Na+/K+-ATPase pump. It has been known for some time that glycolysis is coupled to sodium and potassium 
transport processes, and that some cardiac glycosides (e.g., ouabain) can inhibit glycolysis in a variety of non-malignant cells [25, 26]. It has recently 
been found that cancer cells are more reliant on glycolysis for their survival than non-malignant cells (reviewed in [27, 28]). Based on these findings, we 
previously proposed that cardiac glycosides might inhibit glycolysis in cancer cells and that such inhibition might play a critical role in the selective 
cytotoxicity of some cardiac glycosides (e.g. digitoxin) towards cancer cells [5]. More recently, we showed that an extract from the leaves of the 
cardenolide-containing plant Nerium oleander induced a marked inhibition of glycolysis in lung cancer cells [22]. To test if digitoxin, digoxin and 
ouabain could inhibit glycolysis in A549 lung cancer cells, were exposed these cells to each cardiac glycoside for 8 h, and glucose and lactate 
concentrations were determined in cell supernatants. Results, represented in Illustration 2, show that A549 cells exposed to nanomolar concentrations 
of all three cardiac glycosides exhibited a marked reduction in glucose consumption (A) and lactate production (B), comparable to those observed in 
cells exposed to an equi-toxic concentration of the glycolysis inhibitor dichloroacetate (DCA, 10 mM). No significant changes in glucose consumption and 
lactate production were observed in cells exposed to cisplatin 32 μM. Illustration 2C includes representative photographs of cells exposed for 8 h to each 
drug, where cell number and morphology can be appreciated. These photographs seek to show that the reduction in glucose consumption and lactate 
production induced by the cardiac glycosides is not caused by a reduction in cell number (fewer cells would consume less glucose and would produce 
less lactate). Knowing that glucose and lactate are, respectively, the initial and final products of glycolysis, our data indicate that digitoxin, digoxin and 
ouabain induce a marked inhibition of glycolysis in A549 lung cancer cells at nanomolar concentrations.
The inhibition of glycolysis induced by digitoxin, digoxin and ouabain (Illustration 2) may be mediated by their known ability o inhibit the Na+/K+-ATPase 
pump.  Indeed, several mechanisms have been proposed to explain how the inhibition of the Na+/K+-ATPase pump can lead to glycolysis inhibition [5]. It 
has been proposed that the inhibition of the Na+/K+-ATPase pump would decrease glycolysis activity via inhibition of the key glycolytic enzyme 
phosphofructokinase (discussed in reference [5]). In addition, inhibition of the Na+/K+-ATPase pump may restrict the activity of sodium glucose 
transporters (SGLTs), which couple glucose entry into some types of cells with the activity of this pump [5]. These transporters are typically found in 
small intestine and renal epithelial cells; however, clinical data have revealed that these transporters (SGLT2) are overexpressed in lung cancer cells 
that have metastasized to other organs [29]. This suggests that SGLT2 plays a role in glucose uptake in the metastatic lesions of lung cancer, and that 
inhibition of the Na+/K+-ATPase pump by cardiac glycosides may inhibit glycolysis by reducing glucose entry into the cells. The inhibition of glycolysis 
induced by digitoxin, digoxin and ouabain in A549 lung cancer cells may therefore be caused by inhibition of the Na+/K+-ATPase pump, which would lead 
to both the inhibition of the glycolytic enzyme PFK and the inhibition of glucose entry into the cells.
The inhibition of glycolysis observed in lung cancer cells treated with digitoxin, digoxin and ouabain may play a role in their cytotoxicity. The main 
cellular roles of glycolysis are to provide building blocks for biosynthesis and ATP, and evidence suggests that inhibition of these processes may have a 
higher impact on the viability of cancer cells than on that of non-malignant cells. Indeed, glycolysis inhibition has been proposed to be an anticancer 
strategy to selectively kill cancer cells [27, 28]. Although here we report that digitoxin, digoxin and ouabain induce selective cytotoxicity against lung 
cancer cells and that they induce a potent inhibition of glycolysis in these cells, we cannot conclude that the inhibition of glycolysis is responsible for 
their selective anticancer activity. As discussed previously [22], evidence suggests that the expression and cellular location of Na+/K+-ATPase alpha 
subunits in different types of cells (i.e., rodent cells, human cancer cells and human non-malignant cells) may explain why different cells are more or 
less susceptible to the cytotoxic activity of cardiac glycosides [30-32]. The study of the possible association between the expression and cellular 
location of Na+/K+-ATPase alpha subunits and the ability of cardiac glycosides to inhibit glycolysis would help reveal whether the inhibition of glycolysis 
by these compounds plays a role in their selective cytotoxicity.
Most cancer chemotherapy regimens include a combination of drugs. Since platinum compounds are widely used in the treatment of lung cancer, we 
assessed the cytotoxic activity of digitoxin, digoxin and ouabain in combination with cisplatin in A549 lung cancer cells. Then, we calculated the 
parameter Combination Index (CI) with the computer software Compusyn; this parameter is based on the Chou-Talalay method and offers quantitative 
definition for additive effect, synergism, and antagonism in drug combinations [24]. A549 cells were exposed for 44-48 h to several concentrations of 
cisplatin, each cardiac glycoside and cisplatin in combination with each cardiac glycoside. Cell viability was then estimated with the MTT assay. Results 
are collected in Illustration 3 (digitoxin), Illustration 4 (digoxin) and Illustration 5 (ouabain), and show that these combinations induced synergistic, 
antagonistic or additive effects mainly depending on the concentrations of the drugs and on the order at which they were added to the cells. Evidence 
suggests that the Na+/K+-ATPase alpha1 subunit plays a role in the intracellular accumulation of cisplatin and that cardiac glycosides can reduce its 
intracellular accumulation [33]; this may help explain some antagonisms observed in these Illustrations. The synergisms observed in these illustrations 
with some combinations might be caused by the ability of cardiac glycosides to circumvent a variety of resistance pathways discussed elsewhere [9, 10].
In summary, we report for the first time that the cardiac glycosides digitoxin, digoxin and ouabain induce a potent inhibition of glycolysis in lung cancer 
cells, which may participate in their selective cytotoxicity. We also show that specific combinations of these cardiac glycosides may increase the 
cytotoxicity of platinum compounds, which are commonly used in the treatment of lung cancer.
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